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Abstract (286 words) 
Aims Subunit interactions at the cytoplasmic domain interface (CD-I) have 
recently been shown to control gating in inward rectifier potassium channels. Here we 
report the novel KCNJ2 variant p.Glu293Lys that has been found in a patient with 
Andersen-Tawil Syndrome type 1 (ATS1), causing amino acid substitution at the CD-I 
of the inward rectifier potassium channel subunit Kir2.1. Neither has the role of 
Glu293 in gating control been investigated, nor has a pathogenic variant been 
described at this position. This study aimed to assess the involvement of Glu293 in 
CD-I subunit interactions and to establish the pathogenic role of the p.Glu293Lys 
variant in ATS1. 
Methods and Results The p.Glu293Lys variant produced no current in 
homomeric form and showed dominant negative effect over wild type (WT) subunits. 
Immunocytochemical labelling showed the p.Glu293Lys subunits to distribute in the 
subsarcolemmal space. Salt bridge prediction indicated the presence of an 
intersubunit salt bridge network at the CD-I of Kir2.1, with the involvement of Glu293. 
Subunit interactions were studied by the NanoBiT split reporter assay. Reporter 
constructs carrying NanoBiT tags on the intracellular termini produced no 
bioluminescent signal above background with the p.Glu293Lys variant in homomeric 
configuration and significantly reduced signals in cells co-expressing WT and 
p.Glu293Lys subunits simultaneously. Extracellularly presented reporter tags, 
however, generated comparable bioluminescent signals with heteromeric WT and 
p.Glu293Lys subunits and with homomeric WT channels. 
Conclusions Loss of function and dominant negative effect confirm the causative 
role of p.Glu293Lys in ATS1. Co-assembly of Kir2.1 subunits is impaired in 
homomeric channels consisting of p.Glu293Lys subunits and is partially rescued in 
heteromeric complexes of WT and p.Glu293Lys Kir2.1 variants. These data point to 
an important role of Glu293 in mediating subunit assembly, as well as in gating of 
Kir2.1 channels.  
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Translational perspective (94 words) 
Andersen-Tawil Syndrome (ATS) is a rare genetic disorder characterized by the 
triad of periodic paralysis, dysmorphic features and ventricular arrhythmias. Symptoms 
can be mild and atypical, therefore, genetic screening of affected families is pivotal. 
This study describes the p.Glu293Lys variant of KCNJ2 encoding the Kir2.1 ion 
channel subunit as pathogenic, thereby aiding genetic testing of ATS. The study also 
identifies disturbed interactions between the cytoplasmic domains of Kir2.1 subunits 
as the molecular mechanism of loss-of-function in the p.Glu293Lys variant. Targeting 
cytoplasmic domain interactions may represent a promising strategy for the 
development of Kir2.1 agonists. 
1. Introduction 
Andersen-Tawil Syndrome (ATS) is a rare genetic disorder characterized by the 
triad of periodic paralysis, dismorphic features and cardiac manifestations, such as 
frequent ventricular ectopic activity and the occurrence of sustained ventricular 
arrhythmias1-5. ATS type 1 (ATS1) is caused by mutations in the KCNJ2 gene 
encoding for the inward rectifier potassium channel Kir2.16. Kir2.1 is expressed in 
various tissues including the skeletal muscle and the heart. Kir2.1 can exists either in 
the form of homo- or hetero-tetrameric complexes that consist either four identical 
Kir2.1 subunits or various combinations of the structurally related members of the 
Kir2.x subfamily of inward rectifier potassium channels, respectively (reviewed in7). In 
the skeletal muscle, Kir2.1 combines with Kir2.2 and Kir2.6, whereas in the heart, 
Kir2.1, Kir2.2, Kir2.3 and Kir2.4 subunits co-assemble in a cell type-specific way to 
form ion channels generating the cardiac inwardly rectifying potassium current IK18-10. 
Kir2.1 dysfunction has been shown to underlie pathologies leading to periodic 
paralysis, craniofacial dismorphic features and cardiac symtpoms characteristic to 
ATS111-13. 
Symptomes in ATS1 are often mild and long-term prognosis is thought to be 
relatively more favourable compared to other channelopathies. A recent multicenter 
study on the largest ATS1 patient cohort (n = 118) assembled to date, however, 
showed that adverse cardiac events are more frequent in ATS1 than previously 
anticipated14. Most importantly, pharmacological therapy including the use of β-
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blockers alone or in combination with class Ic antiarrhythmic agents failed to reduce 
the occurrence of life-threathening arrhythmic events, despite suppressing arrhythmic 
symtpomes effectively14. These findings highlight the demand for evidence-based 
treatment strategies in ATS1, including the development of specific activators of IK1. 
Over 70 KCNJ2 mutations causing ATS1 have been described, the majority being 
missense mutations and all but a few have a dominant negative effect over the wild 
type (WT) Kir2.1 variant (reviewed in15). Gating alterations16, 17, defective protein 
trafficking18 and structural changes in the conduction pathway19, 20 have been 
identified as molecular mechanisms underlying loss-of-function of Kir2.1 channels. 
We have identified the KCNJ2 variant p.Glu293Lys in a patient with characteristic 
ATS1 phenotype. The amino acid Glu293 affected in this variant is located in 
cytoplasmic domain at the surface connecting adjacent subunits, the so-called 
cytoplasmic domain interface (CD-I)21. Subunit interactions between Kir subunits at 
the CD-I have recently been demonstrated to control gating of inward rectifier 
channels22-24. Considering the capacity of Glu293 to form salt bridges, a prominent 
role for Glu293 in mediating subunit CD-I interactions may be anticipated. To our 
knowledge, structure-function correlates of Kir2.1 at Glu293 and the surrounding 
region has not been investigated. In the light of the unmet need for a selective IK1 
activator, insights into gating mechanisms and into structure-function relationships of 
Kir2.1-based ion channels might serve as the basis of rational drug design. Hence, 
this study aimed to investigate whether CD-I subunit interactions are affected in the 
p.Glu293Lys variant. Furthermore, since no mutation at codon 293 of KCNJ2 has 
been associated to ATS1, we functionally characterized the p.Glu293Lys variant in 
order to establish the pathogenic role of p.Glu291Lys variant in ATS1, thereby aiding 
future genetic testing. 
2. Methods 
2.1 Patient's case history 
The index patient was referred to the Cardiology Center, University of Szeged, 
Hungary (a European Reference Network GUARD-Heart Affiliated Partner) through a 
nation-wide collaboration aiming to establish centralized screening for patients with 
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ion channel diseases and was one of the six patients which were diagnosed with 
Andersen-Tawil syndrome in the frame of the project. 
The female index patient was diagnosed with ATS1 at age of 7 years. She was 
born from an uneventful pregnancy at the end of 40 gestational weeks, with 2900 g 
birth weight. Dismorphic features were evident at the time of diagnosis and included 
hypertelorism, low-set ears, mandibular hypoplasia, broad nose, and broad forehead. 
Symptomless premature ventricular beats (PVB), which were diagnosed as 
multifocal (with two different PVB morphology), sometimes bigeminal PVBs, with 
short runs of non-sustained ventricular tachycardia (NSVT) were detected at age of 4 
years. On Holter examination, PVBs made up 38% of all recorded beats. Corrected 
QT interval (QTc) was increased and was in the range of 456-485 ms. 
Echocardiography did not reveal any significant structural heart disease. Due to 
regular NSVT, flecainide therapy was initiated at the age of 11 years. Ventricular 
PVBs ceased promptly after the initiation of iv. flecainide and remained so on po. 
therapy (2x100 mg). Beta blocker therapy (propranolol 3x20 mg) was continued. 
Control Holter revealed 0% PVB of all recorded beats. 
Skeletal muscle symptoms, apart of general fatigue and occasional numbness of 
the feet, started to occur as periodical paralysis at age of 8 years. The latter was 
characterized by inability to raise and walk, lasting for 3 days, and was unrelated to 
serum potassium levels (3,86-4,6 mmol/l). Acetazolamide did not significantly 
improve symptoms. The episodes of periodical paralysis became more severe and 
the patient is wheelchair bound at age of 10 years. Flecainide treatment, which was 
shown to be particularly effective in reducing ventricular arrhythmic activity after one-
year follow-up, seemed to have no effect on paralytic symptoms. Paralysis often 
affected all four extremities. The patient's mental development and ability to 
cooperate is according to age. 
At the time of the last visit, the patient was 12 years old. She complains 
retrosternal chest pain, that does not occur at night. Shortness of breath also occurs. 
Respiratory function is in normal range in lying position, while a moderate restrictive 
respiratory dysfunction was demonstrated in upright position, characteristic for 
muscle weakness, possibly indicating intercostal muscle weakness. Rarely, 
abdominal pain develops. Abdominal ultrasound did not confirm any abnormality in 
the localization corresponding to the complaints. 
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2.2 Genetic analysis 
Molecular genetic analysis was approved by the Institutional Ethics Committee of 
the University of Szeged, and conducted according to the Helsinki declaration after 
the patient’s care-givers gave prior written informed consent. Coding sequences and 
exon-intron boundaries of major ion channel and ion-channel related genes, including 
the KCNJ2 gene, were analyzed by next-generation sequencing using Agilent's 
SureSelect technology with custom-designed 120-mer RNA baits specific to target 
region (Agilent Technologies, Santa Clara, CA, United States). The KCNJ2 gene 
sequence variant was validated by Sanger sequencing. Molecular genetic and 
bioinformatic analysis was carried out as described previously25. 
2.3 Plasmid constructs 
The wild type (WT) mouse KCNJ2 cDNA was available from a previous study26, 
whose procedures conformed to the guidelines from Directive 2010/63/EU of the 
European Parliament on the protection of animals used for scientific purposes, point 
mutations c.653G>A and c.877G>A encoding for the p.Arg218Gln and p.Glu293Lys 
variants were introduced using the overlap-extension PCR technique27. WT and 
mutant cDNAs were subcloned in the pcDNA3.1 expression vector and were used in 
the patch clamp and immunocytochemistry experiments. 
Plasmid constructs for the intracellular protein:protein interaction assays were 
generated by following the instructions for the NanoBiT Protein:Protein Interaction 
System (Promega, Madison WI, USA). For the extracellular display of the NanoBiT 
tags, reporter constructs were equipped with an additional transmembrane domain, 
the so-called 'Snorkel' tag, following standard laboratory procedures28. Each resulting 
plasmid construct was sequence verified. A detailed description of the molecular 
cloning procedures is provided in the Supplementary material online. 
2.4 Cell culture and transient transfections 
Human embryonic kidney cells (HEK, ATCC CRL-11268, Manassas, VA, USA) 
were cultured in DMEM : F12 medium (Lonza, Verviers, Belgium) supplemented with 
10% FBS (EuroClone, Pero (MI) Italy) at 37 °C in a humidified atmosphere containing 
5% CO2, Chinese hamster ovary (CHO, ATCC CCL-61, Manassas, VA, USA) cells 
were cultured as described previously26. 25 KDa linear poliethyleneimine (PEI, 
Polysciences Inc., Warrington PA, USA) was used as a transfection reagent, the 
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transfection mixture contained a total amount of 4 µg plasmid DNA and 16 µg PEI in 
1.5 ml reduced serum medium (UltraMEM; Lonza, Verviers, Belgium). In the patch 
clamp expeirments, transfection mixtures contained 1 µg wild type Kir2.1 (WT-Kir2.1) 
or 1 µg mutant cDNA constructs. Co-transfections with WT- and mutant Kir2.1 
variants were carried out with 1 µg WT- and 1 µg mutant cDNA plasmid. A GFP-
encoding plasmid was used to keep DNA content constant in each experimental 
group and as a transfection marker. Transfection mixtures for the NanoBiT 
experiments contained 2 µg of each NanoBiT reporter construct with no GFP-
expressing plasmid added. All subsequent experiments were carried out 48 hours 
post-transfection. 
2.5 Electrophysiology 
Whole cell voltage-clamp experiments were carried out as previously described26. 
Briefly, normal Tyrode solution was used externally, containing (in mmol/L): NaCl 
142, NaH2PO4 0.4, KCl 4, MgSO4 0.53, CaCl2 1.8, glucose 5.5, and HEPES 5; pH 
was adjusted to 7.4 with NaOH. Electrodes were filled with a solution containing (in 
mmol/L): KOH 110, KCl 40, K2ATP 10, HEPES 5, EGTA 5, and MgCl2 0.1; pH was 
adjusted to 7.2 with aspartic acid. Currents were recorded at 37 °C from the GFP- 
positive cells. Cell capacitance was estimated by the integral of the capacitive current 
elicited by a -10 mV hyperpolarizing pulse. Cell capacitance was canceled and series 
resistance was compensated. Voltage error after compensation was below 0.5 mV at 
-60 mV in each experiment. Kir2.1 current amplitudes were recorded as Ba2+-
sensitive (30 µM) current at the end of a 300 ms long pulses to potentials in the 
voltage range of -120 mV to 40 mV with 10 mV increments, with the interpulse 
holding potential set at -80 mV. Current densities were calculated by the current 
amplitude and cell capacitance quotient. 
2.6 Immunocytochemistry 
CHO cells were cultured and transfected according to the protocol described for 
the patch clamp experiments. The cell membrane was labelled with Wheat Germ 
Agglutinin Texas Red-X Conjugate (WGA-TxRed, 1:400, Life Technologies, 
Carlsbad, CA USA), Kir2.1 was labelled by the Anti-Kir2.1 primary antibody (APC-
026, 1:100, Alomone Labs, Jerusalem, Israel) recognizing an epitope on the 
cytoplasmic C-terminus of Kir2.1 and by the subsequently applied FITC-conjugated 
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Anti-Rabbit IgG secondary antibody (1:450, DakoCytomation, Santa Clara CA, USA). 
Fluorescent images were captured by a LSM 880 (Zeiss) laser scanning confocal 
microscope using the Plan-Apochromat 40x/1.4 Oil DIC M27 objective. FITC and 
WGA-TxRed were detected in the 493 – 574 nm and 574 – 689 nm wavelength 
range, respectively. The resulting pixel size was in the range of 0.03 – 0.1 µm 
(meidan 0.04 µm, 25% percentile 0.04 µm, 75% percentile 0.05 µm). Images were 
quantitatively analyzed by the the ImageJ software (1.52p) as the following. A 1 px 
wide line was placed crossing the cell and avoiding the nucleus. The red channel 
showing WGA-TxRed fluorescence was used to identify the membrane (M) and 
cytoplasmic (C) regions independently of Kir2.1 fluorescence. M areas were defined 
by the maximal intensity value and equal number of pixels on both sides of it, all 
together covering a 280 – 320 nm wide area on each edge of the cell. The C region 
was defined as a 490 – 510 nm wide area overlapping with the geometric axis 
between the two membrane regions. Identical pixels corresponding to the M and C 
regions were selected in the green channel showing Kir2.1 immunofluorescence and 
average intensity values were calculated for M and C regions of each cell. 
Perasons`s correlation coefficients for the WGA-TxRed and Kir2.1 
immunofluorescent signals were calculated by the Coloc2 plugin of the ImageJ 
software (version 1.52p) with no filtering or background subtraction applied. 
2.7 Prediction of salt bridges 
Salt bridges were predicted by using the ESBRI software29 in the 1U4F crystal 
structure of the cytoplasmic domain of the WT Kir2.121 and in the 2GIX crystal 
structure of the cytoplasmic domain of mutant Kir2.1 carrying the pathogenic ATS1 
mutation p.Arg218Gln and a rescue mutation p.Thr309Lys20. The 3SPI model of 
Kir2.2 is used for illustration purposes only (Figure 2A)30. The models were obtained 
from the RCSB Protein Data Bank (https://www.rcsb.org/) and were visualized by 
using the RasWin Molecular Graphics software (2.7.5.2.). 
2.8 The NanoBiT structural complementation reporter assay 
3.2 x 106 HEK cells were plated in 6 cm culture dishes on the day before the 
transfection. 48 hours post-transfection, 1.6 x 105 cells were loaded per well in 100 µl 
UltraMEM in a 96-well plate. A five-fold working solution of the cell-permeable 
NanoGlo Live Cell Reagent (Promega, Madison WI, USA) was prepared in a reduced 
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light environment and 25 µl of it was added to the cells per well. The plate was then 
quickly moved into a FLUOstar Optima Microplate Reader (time = 0 min) and was 
read in luminescence mode. Luminescence values were collected every minute for 1 
hour. Luminescence values collected between 16–17 min and between 0-1 min were 
used for statistical analysis with the cytoplasmic and extracellular NanoBiT reporters, 
respectively. Transfections were carried out on separate days containing all 
experimental groups and three replicates for each group in parallel. One data point 
reported corresponds to the numerical average of three parallel replicates. 
2.9 Statistical analysis 
Numerical data in the text are presented as the arithmetic mean of data points 
and the 95% confidence interval of the mean (95% CI [lower limit, upper limit]), in 
order to indicate the range of values which contains the mean of the measured 
parameter of the population of experimental subjects with 95% probability. For the 
same reason, numerical data in the figures are presented as individual values and 
the arithmetic mean ± the lower and upper limits of 95% CI. Luminescence values 
presented in Figure5 and 6 were log-transformed to achieve homogeneous variance. 
Group means were compaired either by Student's t-test or by one-way ANOVA 
followed by post hoc tests with Bonferroni's correction for multiple comparisons by 
using the Graphpad Prism software (version 8.1.1). 
3. Results 
3.1 Genetic analysis 
The NM_000891.2: c.877G>A (p.Glu293Lys) heterozygous genetic variant in the 
KCNJ2 gene has been detected using targeted resequencing and was validated by 
standard capillary sequencing. This variant has not been reported previously, nor 
was it present in 374 control chromosomes representing subjects from the same 
geographical area. The mutation was not detected in the clinically unaffected parents 
and brother of the proband (data not shown), indicating that the mutation may have 
arisen ‘de novo’ (paternity proven). No mutations were found in the proband in any 
other member of the KCNJ gene family. The p.Glu293Lys variant was regarded as 
‘pathogenic’ according to the joint consensus recommendation of the American 
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College of Medical Genetics and Genomics and the Association for Molecular 
Pathology31. 
3.2 Electrophysiological characterization of the p.Glu293Lys Kir2.1 variant 
WT and mutant Kir2.1 subunits were heterologously over-expressed in CHO cells. 
Cells expressing the WT Kir2.1 alone or in combination with p.Glu293Lys exhibited 
robust inward current with strong inward rectification (Figure 1A). Current amplitudes 
were markedly reduced when cells were transfected with the combination of cDNAs 
encoding the WT and p.Glu293Lys variants (Figure 1A). No current was detected in 
cells expressing the p.Glu293Lys variant alone (n = 10, Figure 1A). The outward 
component of the current-voltage relationships measured at the physiologically 
relevant membrane potential range between -80 to 0 mV was prominent (Figure 1B). 
To assess conductivity of Kir2.1-based ion channels in the presence and in the 
absence of the p.Glu293Lys variant, current densities that were recorded at the test 
potential -60 mV were compared. The KCNJ2 allele p.Arg218Gln with loss of function 
and dominant negative effects and with well documented pathogenic role in ATS1 
has been included as positive control (Figure 1B)16, 32. Average current densities 
were the highest in cells expressing WT Kir2.1 alone (9.6 pA / pF, 95% CI [7.2, 12.0], 
n = 15, Figure 1B). Current densitites with p.Glu293Lys or with the p.Arg218Lys 
variants were practically non-detectable (-0.2 pA / pF, 95% CI [-0.8, 0.3], n = 7 and 0 
pA / pF, 95% CI [-0.7, 0.6], n = 9, respectively) and were significantly lower compater 
to WT (p < 0.0001 in both cases, Figure 1B). Modelling the heterozygous patient 
genotypes by co-expression of WT and mutant KCNJ2 variants resulted in 
significantly decreased average current densities both with the p.Glu293Lys (3.6 pA / 
pF, 95% CI [1.7, 5.6], n = 10, p = 0.0006) and the p.Arg218Gln variant (4.5 pA / pF, 
95% CI [1.6, 7.5], n = 10, p = 0.0045) compared to homomeric WT channels (Figure 
1B). In summary, these data indicate a prominent dominant negative effect of the 
p.Glu293Lys variant over WT channels, resulting in loss of function on the 
heterozygous genetic background. 
3.3 Intersubunit salt bridges predicted in the vicinity of Glu293 
Tetrameric complexes of ion channels based on Kir2.x subunits consist of two 
distinct structural domains, the membrane-spanning transmembrane domain (TD) 
and the cytoplasmic domain (CD, Figure 2A). The glutamic acid at position 293, that 
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is substituted to lysine in the p.Glu293Lys variant, is located in the cytoplasmic 
domain at the surface connecting two adjacent subunits, also known as the CD-I 
region (Figure 2B). Glutamic acid has the capacity to form salt bridges with positively 
charged resdues, when in the proximity to each other. Since salt bridges can mediate 
subunit interactions and such interactions have been shown to have profound effects 
on Kir2.1 gating, we asked whether or not Glu293 can be involved in the formation of 
salt bridges. To this end, salt bridges were predicted in the 3D crystallography 
models of the Kir2.1 cytoplasmic domain (1U4F and 2GIX) by using the ESBRI 
software29. According to these predictions, Glu293 participates in a network of salt 
bridges. There are four amino acids involved. Glu319 is located in the same subunit 
proximal to Glu293, while Arg46 and Lys50 are situated in the opposite subunit. One 
salt bridge was predicted between Glu293 and Arg46, two between Arg46 and 
Glu319 and an additional one between Glu319 and Lys50 (Figure 2C). Each of these 
four salt bridges are formed between amino acids that reside in different subunits and 
therefore connect two subunits to each other. Because of the four-fold symmetry of 
the Kir2.x ion channel complex, anaolgous CD-I regions are present between each 
adjacent subunit pair. The same set of salt bridges were predicted at all four locations 
in both protein structure models. A complete list of the predicted salt bridges in the 
region is provided in Supplementary material Table S1. The charge reversal at 
position 293 in the p.Glu293Lys variant, therefore, may be expected to impair this 
intersubunit salt bridge network and to prevent the formation of 4 salt bridges 
between cytoplasmic domains of adjacent Kir2.1 subunits. Moreover, alignment of 
amino acid sequences revealed that Arg46, Lys50, Glu293 and Glu319 are highly 
conserved in Kir2.1 proteins from vertebrate species and in the human inward 
rectifier potassium channel protein family, suggesting a crucial role for these amino 
acids and the predicted intersubunit salt bridge network in structure-function 
relationships of inward rectifier potassium channels (Figure 2D). 
3.4 Assessment of subcellular localization 
Intersubunit salt bridges can stabilize the binding of monomers in protein 
complexes and mediate subunit assembly. We hypothesized, therefore, that the 
disruption of the predicted salt bridge network at the CD-I in the p.Glu293Lys variant 
might affect co-assembly of Kir2.1 subunits, which in turn might result in the 
cytoplasmic accumulation of misfolded protein complexes. To assess this possibility, 
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the subcellular localization of the heterologously over-expressed WT, p.Glu293Lys 
and p.Arg218Gln Kir2.1 variants was assessed and compared by immunofluorescent 
labelling and confocal microscopy (Figure 3). Visual observation of confocal images 
showed prominent labelling of the cell membrane (Figure 3A), line profiles consisting 
of pixel intensity values along a 1 pixel wide line placed crossing the cytoplasm but 
not the nucleus showed intensity peaks near the edges of the cell (Figure 3B). 
Membrane (M) and cytoplasmic (C) regions were then defined for each cell, based on 
the fluorescent signal of the aspecific membrane dye WGA-TxRed. Average Kir2.1 
immunofluorescense signal intensities were significantly higher in the M compared to 
the C area with all three variants (p < 0.0001, Figure 3C). Fold difference of average 
M versus C Kir2.1 expression were similar in all experimental groups, with a 
statistically non-significant decrease with the p.Glu293Lys variant (p=0.12, Figure 
3D). Colocalization of the Kir2.1 immunofluorescence with WGA-TxRed fluorescence 
was then assessed by calculating Person`s correlation coefficients (PCC). While 
average PCC values were similar with the WT and p.Arg218Gln variants, significantly 
lower PCC values were found in cells expressing p.Glu293Lys subunits (0.68, 95% 
CI [0.63, 0.73], n=11) both compared to WT (0.81, 95% CI [0.77, 0.85], p = 0.0002, 
n=13) and p.Arg218Gln (0.82, 95% CI [0.78, 0.86], p < 0.0001, n=12) groups (Figure 
3E). Therefore, we found that while an obvious cytoplasmic accumulation is not 
evident, the p.Glu293Lys variant tends to distribute less in the cell membrane. These 
data suggest that oligomerization of the p.Glu293Lys variant into a homo-tetrameric 
complex is deficient and that misfolded p.Glu293Lys subunits distributre preferentially 
in the submembrane area. 
3.5 Assessing physical interaction between Kir2.1 subunits 
To confirm and further explore deficient oligomerization of the p.Glu293Lys Kir2.1 
variant, two distinct variations of the NanoBiT assay was developed (Figure 4A, 
6A)33. The NanoBiT assay is based on the complementation of the large (LgBiT) by 
the small (SmBiT) fragments of the split NanoLuc luciferase enzyme. The LgBiT and 
SmBiT fragments complement each other and form a functional enzyme when in the 
proximity of each other33. Therefore, LgBiT and SmBiT fragments can be used as 
reporter tags to investigate portein:protein interactions, including intersubunit 
interactions within the ion channel complex. First, the LgBiT and SmBiT tags were 
fused to the cytoplasmic C-termini of Kir2.1 subunit variants (Figure 4A). To assess 
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subunit interactions in homomeric Kir2.1 channels, HEK cells were co-transfected 
with LgBiT- and SmBiT-tagged, but identical KCNJ2 variants. When identical Kir2.1 
variants tagged with either NanoBiT fragment were co-expressed, average loge 
luminescence (ln(RLU)) values were similar in cells transfected with WT-LgBiT and 
WT-SmBiT (6 ln(RLU), 95% CI [5.2, 6.9], n = 4) and in cell co-expressing the 
p.Arg218Gln reporter pair (6 ln(RLU), 95% CI [5.4, 6.6], n = 4, p > 0.9999). In 
contrast, ln(RLU) values were significantly lower in cells expressing the p.Glu293Lys 
reporter constructs (4.3 ln(RLU), 95% CI [3.3, 5.3], n = 4), both compared to 
homomeric combinations of the WT (p = 0.0033) or the p.Arg218Lys variant (p = 
0.0045, Figure 4B). Furthermore, these latter values were statistically 
indistinguishable from cells expressing WT-SmBiT and the LgBiT-tagged, structurally 
unrelated, six-transmembrane-domain voltage-gated potassium channel subunit 
KvLQT1 used as a negative control (4 ln RLU, 95% CI [3, 4.9], n = 4, p > 0.9999, 
Figure 4B). To model the heterozygous genotype, experiments were carried out with 
the intracellular NanoBiT constructs in cells co-expressing the appropriate reporter 
pair of the WT and each mutant KCNJ2 variant (Figure 4C). Mean ln(RLU) values 
were not different in cells expressing WT-LgBiT and p.Arg218Gln-SmBiT (6.6 
ln(RLU), 95% CI [6, 7.1], n = 5) compared to the positive control (WT-LgBiT + WT-
SmBiT: 6.4 ln(RLU), 95% CI [5.9, 7.2], n = 5, p > 0.9999, Figure 4C). Interestingly, 
co-transfection of WT-LgBiT with p.Glu293Lys-SmBiT produced luminsecence values 
(5.6 ln(RLU), 95% CI [5.1, 6.1], n = 5) that were significantly lower compared to the 
positive control (p = 0.0266), but significantly higher than the negative control (WT-
SmBiT + KvLQT1-LgBiT: 4.4 ln(RLU), 95% CI [3.9, 4.9], n = 5, p = 0.0042, Figure 
4C). These data indicate that the oligomerization of Kir2.1 subunits is impaired in the 
presence of p.Glu293Lys, but not the p.Arg218Gln mutation. Importantly, 
p.Glu293Lys subunits are still able to form heteromers with WT subunits, although to 
a lower extent compared to WT or to p.Arg218Gln variants. 
If p.Glu293Lys and WT subunits are able to co-assemble to a certain extent, they 
might be able to form properly folded heteromeric complexes that are transported to 
and are present in the cell membrane. To test this possibility, the extracellular variant 
of the NanoBiT assay was applied (Figure 5). In these reporter constructs, an extra 
transmembrane domain, the so-called Snorkel tag (-Sn-) is fused to the C-termini of 
Kir2.1 subunits, which are further extended by the NanoBiT fragments, so that the 
LgBiT and SmBiT reporter tags are displayed extracellularly (Figure 5A). The 
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extracellular presentation of the Snorkel-NanoBiT fragments could be verified by 
observing the time course of the development of the bioluminescent signal 
(Supplementary Figure S1). When the cytoplasmic NanoBiT reporters were used, 
maximal bioluminescent signal intensities were reached at 15.6 minutes on average. 
This relatively slow signal development can be attributed to the time needed for the 
cell-permeable substrate of NanoLuc to perfuse the cell interior. In sharp contrast to 
this, the Snorkel-NanoBiT reporters generated the maximal bioluminescent intensities 
typically at the earliest time point (Supplementary Figure S1), indicating the 
presence of the reconstituted NanoLuc on the extracellular side of the membrane. 
Hence, to gain information on the membrane-resident fraction of the Snorkel-
NanoBiT reporter constructs, in these experiments, bioluminescent intensities 
collected at 0 min were compared. 
Average ln(RLU) values were not different in the positive control (WT-Sn-LgBiT + 
WT-SN-SmBiT: 6.8 ln(RLU), 95% CI [6.1, 7.4], n = 6), in cells expressing 
p.Arg218Gln-Sn-LgBiT and WT-Sn-SmBiT (7.4 ln(RLU), 95% CI [6.6, 8.1], n = 6, p = 
0.5406) or in cells that were co-transfected with p.Glu293-Sn-LgBiT and WT-Sn-
SmBiT reporters (6.8 ln(RLU), 95% CI [6.1, 7.5], n = 6, p > 0.9999, Figure 5B). On 
the other hand, each of these group means were significantly higher compared to 
that of the negative control group (4.5 ln RLU, 95% CI [4, 5], n = 6, p < 0.0001 for 
both comparisons), in which KvLQT1, tagged with LgBiT was co-expressed with WT-
Sn-SmBiT (Figure 5B). These data with the extracellular Snorkel-NanoBiT reporters 
indicate that both the p.Arg218Gln and the p.Glu293Lys variants co-assemble with 
WT subunits and heteromeric complexes composed of WT and either of the mutant 
variants exist in the cell membrane. 
Based on these evidence we conclude that the p.Glu293Lys, but not the 
p.Arg218Gln variant affects heteromerization of Kir2.1 subunits, as demonstrated by 
immunocytochemistry and by the experiments with the cytoplasmic NanoBiT reporter 
constructs. On the other hand, the p.Glu293Lys variant is still able to co-assemble 
with WT subunits, although to a lower degree, and these heteromeric ion channels 
are present in the cell membrane. Furthermore, the amount of the membrane-
resident heteromeric channels containing p.Glu293Lys subunits is similar to 
homomeric WT channels, but current amplitudes are reduced in the presence of the 
p.Glu293Lys variant. Therefore, we conclude that in addition to subunit 
heteromerization, Glu293 has an important role in maintaining Kir2.1 channel 
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conductivity, possibly mediated by an intersubunit salt bridge network at the CD-I of 
Kir2.1 channels. 
4. Discussion 
Despite the efforts taken towards the refinement of the ATS1 phenotype, 
phenotypic variability and the incidence of atypical cases seem to be common in 
ATS134, 35. Efficient genetic screening of affected kindreds supports early diagnosis 
and establishment of adequate management. Therefore, the identification and 
functional characterization of pathogenic KCNJ2 variants with the aim to define 
genotype-phenotype correlations is paramount. 
In the present study, the novel causative ATS1 mutation p.Glu293Lys is reported. 
We demonstrate that p.Glu293Lys causes loss of function and exerts a dominant 
negative effect on Kir2.1 currents, as indicated by the patch clamp experiments. 
Importantly, the dominant negative effect was detected over a physiologically 
relevant membrane potential range between -70 mV to -10 mV and it was 
comparable to that of a well-known ATS1 variant p.Arg218Gln32. These findings 
demonstrate the causative role of the p.Glu293Lys mutation in ATS1. 
Salt bridges, electrostatic interactions between an Aspartic or Glutamic acid and 
an Arginine, Lysine or Histidine stabilize folded protein structures and mediate 
subunit interactions. Gating of inward rectifier potassium channels has recently been 
shown to be dependent on intersubunit salt bridges linking Kir subunits within the ion 
channel complex 22, 23. It has been demonstrated that destabilizing the intersubunit 
salt bridges at the CD-I of inward rectifiers results in a substantial dilation (10-20 Ä) of 
the cytoplasmic domain and favors an inactivated state with lower open probability of 
the channel23. Therefore, it seems that the strength of CD-I interactions within the 
cytoplasmic domain has a pivotal role in gating of inward rectifier potassium 
channels. Our study corroborates the above findings and exemplifies the functional 
consequense of impaired CD-I interactions by clinical observations. 
In this study, we investigate intersubunit interactions within the Kir2.1 ion channel 
complex in the presence of the clinically relevant Kir2.1 variants p.Glu293Lys and 
p.Arg218Gln, by using two distinct versions of the NanoBiT split reporter assay. The 
NanoBiT split reporter assay is based on the structural complementation between 
two fragments of the NanoLuc luciferase, the 1.3 kDa SmBiT peptide and the 18 kDa 
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LgBiT polypeptide33. The LgBiT and SmBiT fragments have been selected to have 
the lowest binding affinity to each other, which ensures that a functional, 
bioluminescent enzyme is formed only when there is association between the target 
proteins. In addition, we employed the Snorkel tag schema to display the reporter tag 
pair on the extracellular side of the cell membrane28. The distinctly different time 
course of signal development with the Snorkel- compared to cytoplasmic NanoBiT 
reporter constructs allowed us to gain qualitative and quantitavie information on the 
subunit composition of the membrane-resident fraction of heteromeric Kir2.1 ion 
channels. The NanoBiT assay has recently been used in studies on subunit 
interactions of the A3 adenosine receptor36, on the subunit assembly of the NADH 
oxidase 437 and for the real time monitoring of cullin1 neddylation38. Heteromeric 
assembly of the pore-forming subunits of potassium channels is a general 
phenomenon underlying an enormous functional diversity, however, the full spectrum 
of possible subunit interactions has not been explored yet (reviewed in39). To our 
knowledge, the present study is the first to demonstrate the applicability of the 
NanoBiT assay to investigate subunit interactions of potassium channels, thus 
representing a novel experimental approach in this area. 
Allosteric modulation of protein oligomerization including stabilization of 
protei:protein interactions are emerging concepts of drug discovery (reviewed in40, 41). 
Flecainide, propafenone, nadolol and zacopride have been shown to increase IK1, but 
no specific activators of IK1 have been identified to date42-44. Therefore, it is tempting 
to speculate whether the CD-I of Kir2.1 could represent a promising target for the 
development of IK1 agonists that modulate IK1 via strengthening intersubunit 
interactions at the CD-I. 
It is important to note that the amino acid Arg218 that is substituted by Gln in the 
p.Arg218Gln variant is located at the surface of the cytoplasmic domain of Kir2.1, 
distant from the CD-I20, 21. Arg218 resides in the amino acid cluster mediating the 
binding of PIP2, a major activator of Kir2.1 channels16, 21. Furthermore, the 
p.Arg218Gln variant has been shown to cause displacement of the cytoplasmic G-
loop, a key structural element in the K+ permeation pathway20. Therefore, the 
molecular mechanisms leading to loss of function in the p.Glu293Lys and the 
p.Arg218Gln variants are distinctly different. Indeed, the behavior of the p.Arg218Gln 
was qualitatively and quantitatively similar compared to WT subunits in both 
variations of the NanoBit assays. 
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Our data indicate, that p.Glu293Lys is a novel causative KNCJ2 variant in ATS1, 
exerting dominant negative effect on the WT allele on a heterozygous genetic 
background. Furthermore, Glu293 plays an important role in mediating subunit 
interactions within the Kir2.1 ion channel complex, possibly maintaining a salt bridge 
network at the CD-I. The charge reversal in the p.Glu293Lys variant leads to 
impaired subunit co-assembly in homomeric channels consisting of p.Glu293Lys 
subunits and to gating abnormalities in heteromeric complexes of WT and 
p.Glu293Lys subunits. 
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10. Figure legends 
Figure 1. Electrophysiological characterization of the p.Glu293Lys Kir2.1 variant 
by whole-cell voltage clamp experiments in transiently transfected CHO cells. A: 
Representative current recordings obtained from cells expressing the wild type (WT) 
or mutant (p.Glu293Lys) variants alone or simultaneously (WT + p.Glu293Lys). B: 
Current-voltage relationships. The outward component of Kir2.1 currents detected 
between -80–0 mV are shown in the bottom panel. C: Current densities elicited by a -
60 mV test pulse. Data are presented as mean ± 95% CI. *: p < 0.05, **: p < 0.01, ***: 
p < 0.001 vs WT by one-way ANOVA with Bonferroni’s correction for multiple 
comparisons. 
 
Figure 2. A: The 3D crystallography modell of the Kir2.2 ion channel complex 
(3SPI). TD: transmembrane domain, CD: cytoplasmic domain. B: The cytoplasmic 
domain of Kir2.1 in the 1U4F model (upper view). C: Up-close view of the region 
harboring the amino acids involved in the formation of the predicted salt bridge 
network in the 1U4F model. Atoms are designated according to the PDB 
nomenclature, salt bridges are indicated by the dashed yellow lines. D: Alignment of 
amino acid sequences of human (h), mouse (m), rat (r), guinea pig (gp), dog (d), 
Xenopus tropicalis (x) and zebra fish (zf) Kir2.1 (upper panel) and alignment of amino 
acid sequences of human inward rectifier potassium channel subunits (lower panel). 
Positions indicated are relative to the amino acid sequence of human Kir2.1, 
conserved amino acids are shown in blue shading. Glu293 and its interacting 
partners predicted to participate in the salt bridge network (Arg46, Lys50, Glu319) are 
highlighted in red. 
 
Figure 3. A: Representative photomicrographs show preferential labelling of the 
plasma membrane both with WGA Texas red and anti-Kir2.1 staining. The scale bar 
represents 10 µm. B: Line profiles of cells with anti-Kir2.1 staining from panel A. Pixel 
intensities were normalized to the maximal intensity value for each cell. C: Statistical 
analysis of average pixel intensities in the membrane (M) and in the cytoplasmic (C) 
region. D: Relative pixel intensities in the M vs C regions. E: Fluorescence 
colocalization analysis. (n=13 in WT, n=12 in p.Arg218Gln and n=11 in the 
p.Glu293Lys group). Data are presented as mean ± 95% CI. ***: p < 0.001 by 
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Student’s t-test vs the M region (C) and one-way ANOVA followed by post-hoc tests 
with Bonferroni’s correction for multiple comparisons (D and E). 
 
Figure 4. Subunit interactions within the Kir2.1 complex as assessed by 
intracellular NanoBiT reporter constructs. A: Schematic structure of the intracellular 
NanoBiT reporters showing two opposite Kir2.1 subunits carrying the intracellular 
NanoBiT reporter tag pair. B: Relative loge luminescence (ln(RLU)) readings from 
cells expressing combinations of LgBiT- and SmBiT-tagged Kir2.1 variants in 
homomeric (i.e. WT + WT or mutant + mutant) configuration. C: Ln(RLU) from HEK 
cells co-expressing wild type (WT) and mutant (p.Arg218Gln or p.Glu293Lys) Kir2.1 
subunits tagged with intracellular NanoBiT reporter constructs. Data are presented as 
mean ± 95% CI of log-transformed values (n=4 in panel B and n=5 in panel C). *: p < 
0.05, **: p < 0.01, n.s: non-significant by one-way ANOVA followed by post-hoc tests 
with Bonferroni’s correction for multiple comparisons. 
 
Figure 5. Subunit interactions within the Kir2.1 complex as assessed by 
extracellular NanoBiT reporter constructs. A: Schematic strucutre of the extracellular 
Snorkel-NanoBiT reporters, showing two opposite subunits assembled in the 
tetrameric Kir2.1 complex. A transmembrane domain (Snorkel TMD) was fused to the 
cytpolasmic C-terminus of Kir2.1 so that the NanoBiT reporter tag pair (LgBiT and 
SmBiT) is presented extracellularly. TD: transmembrane domain, CD: cytoplasmic 
domain. B: Relative loge luminescence (ln(RLU)) from HEK cells co-expressing the 
Snorkel-NanoBiT reporter constructs (Sn-LgBiT or Sn-SmBiT). WT-Sn-LgBiT + WT-
Sn-SmBiT co-expression was used as positive control, the structurally unrelated six-
transmembrane-domain potassium channel subunit KvLQT1 tagged with LgBiT co-
expressed with WT-Sn-SmBiT was used as a negative control. Data are presented 
as mean ± 95% CI of log-transformed values (n=6). ***: p <0.001, n.s: non-significant 
by one-way ANOVA followed by post-hoc tests with Bonferroni’s correction for 
multiple comparisons. 
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